The RadioRx Recipe

Take the large defense company contractor, ATK, mix in 1 part venture capital from InterWest Partners, and 1 part Stanford University academic expertise, add a brilliant blending of individual contributions from Dr. Mark Bednarski, organic chemist and physician, who hypothesized the ideal molecule for the treatment of cancer, Dr. Susan Knox, radiation oncologist, who directed exhaustive animal tests which demonstrated that RRx-001 was effective and suitable for clinical trials in man for cancer; Dr. Tony Reid, oncologist, who combines creativity, competence, care and compassion in his role as PI for the RadioRx Phase I study, liberally apply a sprinkling of magic, creativity, innovation, and, yes, even love, and—voila—you have the recipe for a wonderfully unconventional Silicon Valley-based biotechnology company dedicated to improving the human condition called RadioRx, Inc.

RRx-001 Overview

RadioRx’s lead compound is called RRx-001, a structurally unique pharmacophore with novel mechanisms of action (MOA) that are not cross-resistant with approved therapies and that selectively target the microenvironment of the tumor vasculature through a self-amplifying cycle of nitric oxide, free radical, chemokine and cytokine generation under hypoxia. Since RRx-001 increases oxidative stress in tumors, it literally represents a radical approach to cancer treatment.